<DOC>
	<DOC>NCT00181012</DOC>
	<brief_summary>This study will evaluate the benefit of lidocaine perfusion in cancer related visceral pain resistant to morphinics. It is an efficacy study in adults and children and a randomized prospective study.</brief_summary>
	<brief_title>Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics</brief_title>
	<detailed_description />
	<mesh_term>Visceral Pain</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Patients suffering from cancer of any type, at any stage, hospitalized at the Institut Gustave Roussy Aged from 6 to 14 years old (group A) and from 15 to 70 years old (adults) Presenting visceral pain due to neurotoxic chemotherapy, due to the tumoral mass or to peritoneal carcinosis Pain resistant to morphinic treatment Cardiac troubles, clinical cardiac insufficiency, or history of myocardial infarction (MI) of less than 3 months Neurological: noncontrolled epilepsy, encephalopathy, or dementia Severe hepatic insufficiency Severe renal insufficiency Respiratory insufficiency Patients having surgery or in postoperative period Known deficit in G6PD, alanine exposure, or sulphamide treatment Porphyria Weight &gt; 80 kg</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Cancer Related Visceral Pain Resistant to Morphinics</keyword>
</DOC>